[LCID Study Number: 20203202]

An Observational Study Of Ocrelizumab - Treated Patients With Multiple Sclerosis To Determine The Incidence And Mortality Rates Of Breast Cancer And All Malignancies (Verismo Study)

The purpose of this study is to determine the incidence rate of breast cancer and all malignancies following the first ocrelizumab treatment among patients with multiple sclerosis (MS).

Disease/Condition: Multiple Sclerosis

Department: Neurology

Location(s): Lahey Hospital & Medical Center (Burlington)

Primary Contact Email: [email protected]